A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
Paused · Phase 1/Phase 2
Conditions studied: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
In brief
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.
Key facts
- Study ID
- NCT05138458
- Run by
- Myeloid Therapeutics
- People needed
- 40
- Starts
- 2021-12-15
- Expected to finish
- 2025-10-01
- Last updated by the study team
- 2023-11-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope Comprehensive Cancer Center — Duarte, California, United States
- Colorado Blood Cancer Institute — Denver, Colorado, United States
- Dana-Farber/Mass General Brigham Cancer Care — Boston, Massachusetts, United States
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.